Genpact Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 8-K

---

 CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2025

---

GENPACT LIMITED

(Exact name of registrant as specified in its charter)

---

Canon's Court, 22 Victoria Street

Hamilton HM 12, Bermuda

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (441) 298-3300

Not Applicable

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

---

Notes Offering

On November 18, 2025, Genpact UK Finco plc (“Genpact UK”) and Genpact USA, Inc. (“Genpact USA”), indirect wholly owned subsidiaries of Genpact Limited (“Genpact”), completed their previously announced underwritten public offering (the “Notes Offering”) of $350 million aggregate principal amount of their 4.950% Senior Notes due 2030 (the “2030 Notes”). The 2030 Notes are Genpact UK’s and Genpact USA’s senior unsecured indebtedness and are guaranteed on a senior unsecured basis by Genpact and Genpact Luxembourg S.à r.l. (“Genpact Luxembourg”). The 2030 Notes were issued pursuant to an indenture dated as of November 18, 2025 (the “Base Indenture”) among Genpact UK, Genpact USA, Genpact, Genpact Luxembourg and Computershare Trust Company, National Association, as trustee (the “Trustee”), and a first supplemental indenture dated as of November 18, 2025 (the “First Supplemental Indenture”).

The 2030 Notes have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291491), as supplemented by the prospectus supplement dated November 13, 2025, filed with the Securities and Exchange Commission under the Securities Act.

In connection with the issuance of the 2030 Notes, Genpact, Genpact UK, Genpact USA and Genpact Luxembourg entered into an Underwriting Agreement dated as of November 13, 2025 (the “Underwriting Agreement”), among Genpact UK and Genpact USA, as co-issuers, Genpact and Genpact Luxembourg, as guarantors, and the representatives of the several underwriters named therein (the “Underwriters”), pursuant to which Genpact UK and Genpact USA agreed to issue and sell the 2030 Notes to the Underwriters. For a complete description of the terms and conditions of the Underwriting Agreement, please refer to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto, and is incorporated herein by reference.

The 2030 Notes will mature on November 18, 2030. Interest on the 2030 Notes accrues at the rate of 4.950% per annum and is payable semi-annually in arrears on May 18 and November 18 of each year, commencing on May 18, 2026.

The 2030 Notes and the related guarantees are general unsecured obligations of Genpact UK, Genpact USA, Genpact and Genpact Luxembourg, as applicable, and will be pari passu in right of payment with all existing and future senior indebtedness of such entities, will be effectively subordinated to all future secured indebtedness of such entities to the extent of the value of the assets securing that indebtedness and will be senior in right of payment to all future subordinated indebtedness of such entities. The 2030 Notes will be structurally subordinated to all indebtedness and other liabilities of subsidiaries of Genpact (other than Genpact UK, Genpact USA and Genpact Luxembourg) that do not guarantee the 2030 Notes, including the liabilities of certain subsidiaries pursuant to Genpact’s senior credit facility.

Genpact UK and Genpact USA may redeem some or all of the 2030 Notes prior to October 18, 2030 at a redemption price equal to 100% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the redemption date, plus an applicable “make-whole” premium. Genpact UK and Genpact USA may redeem some or all of the 2030 Notes on or after October 18, 2030 at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to, but not including, the redemption date.

The 2030 Notes are subject to certain customary covenants, including limitations on the ability of Genpact and certain of its subsidiaries, including Genpact UK and Genpact USA, with significant exceptions, (i) to incur debt secured by liens; (ii) to engage in certain sale and leaseback transactions; and (iii) to consolidate, merge, convey or transfer their assets substantially as an entirety. In addition, pursuant to a customary change of control covenant, upon a change of control repurchase event, Genpact UK and Genpact USA will be required to make an offer to repurchase the 2030 Notes at a price equal to 101% of the aggregate principal amount of such 2030 Notes, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

Genpact intends to use the net proceeds from the Notes Offering for general corporate purposes, which may include repaying or redeeming Genpact Luxembourg’s and Genpact USA’s outstanding 1.750% senior notes due 2026 (the “2026 Notes”) at or prior to their maturity on April 10, 2026.

Third Supplemental Indenture to 2021 Base Indenture

On November 18, 2025, Genpact Luxembourg, Genpact USA, Genpact, Genpact UK and the Trustee entered into a third supplemental indenture to the indenture dated as of March 26, 2021 among Genpact Luxembourg, Genpact USA, Genpact and the Trustee (the “2021 Base Indenture”), pursuant to which Genpact UK agreed to fully and unconditionally guarantee all of the 2026 Notes and all of Genpact Luxembourg’s and Genpact USA’s 6.000% senior notes due 2029 (the “2029 Notes”) (the “2021 Third Supplemental Indenture”) on the terms, and subject to the conditions and limitations set forth in, the 2021 Base Indenture.

The foregoing descriptions of the Base Indenture, the First Supplemental Indenture, the 2030 Notes and the 2021 Third Supplemental Indenture are qualified in their entirety by reference to the actual terms of the respective documents. Copies of the Underwriting Agreement, the Base Indenture, the First Supplemental Indenture, the form of the 2030 Notes and the 2021 Third Supplemental Indenture are attached as Exhibits 1.1, 4.1, 4.2, 4.3 and 4.4 hereto, respectively, and each is incorporated by reference herein.

The information contained in Item 1.01 is incorporated by reference in this Item 2.03.

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

* Schedules or similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Genpact hereby undertakes to furnish copies of any of the omitted schedules or similar attachments upon request by the Securities and Exchange Commission.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---